April 29, 2021 News by Marisa Wexler, MS #AANAM – Exploring Mavenclad’s Effects on Immune Cells Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read stories from the conference. After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected…
April 28, 2021 News by Marisa Wexler, MS #AANAM – Research Focuses on Measuring Therapeutic Lag Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read the latest stories from the conference. A novel method to calculate how long it takes therapies for multiple sclerosis (MS) to become fully effective…
April 28, 2021 News by Forest Ray PhD #AANAM – Vumerity Showing Tolerability, Efficacy in Ongoing EVOLVE-MS-1 Trial Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Vumerity (diroximel fumarate) continues to be safe and well-tolerated, in addition to reducing measures of disease activity in people…
April 27, 2021 News by Marisa Wexler, MS #AANAM – Early Ocrevus Treatment Helps to Protect Nervous System Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Treating multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage…
April 27, 2021 News by Forest Ray PhD #AANAM – Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. A majority of the relapsing-remitting multiple sclerosis (RRMS) patients given Mavenclad (cladribine) tablets in the CLARITY Phase 3 trial did…
April 27, 2021 News by Marisa Wexler, MS #AANAM – Ocrevus, Rituximab Linked to More Severe COVID-19 Cases in Italy Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Disease-modifying therapies (DMTs) that target CD20 are associated with worse outcomes from COVID-19 in multiple sclerosis (MS) patients, an…
April 23, 2021 News by Marisa Wexler, MS #AANAM – Tysabri Improves Quality of Life, Can Reduce Infection Risk Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Treatment with Tysabri (natalizumab) can improve mental and social health in people with multiple sclerosis (MS), according to new…
April 23, 2021 News by Marisa Wexler, MS #AANAM – COVID-19 Often Leads to Flares in MS Patients, Survey Finds Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. The majority of people with multiple sclerosis (MS) experience new or worsening symptoms after developing COVID-19, a patient survey…
April 23, 2021 News by Marisa Wexler, MS #AANAM – Abnormally Warm Weather Tied to More ER Visits Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. When the weather is unusually warm, people with multiple sclerosis (MS) are more likely to require emergency medical care,…
April 22, 2021 News by Forest Ray PhD #AANAM – Ublituximab Reduced Relapse Rate, Disability Progression in Twin Trials Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Ublituximab, an investigational therapy for relapsing forms of multiple sclerosis (MS), significantly outperformed Aubagio (teriflunomide) at reducing patients’…
April 22, 2021 News by Marisa Wexler, MS #AANAM – More Diversity Needed Among Neurologists, Presenters Agree Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. There is a lack of diversity among neurologists, who are disproportionately white men, but new programs aimed at inclusivity may…
April 21, 2021 News by Marisa Wexler, MS #AANAM – Disease Severity, Job Loss Higher in Black Than White Patients in US Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. African Americans with relapsing-remitting multiple sclerosis (RRMS) are more likely than white patients — despite comparable disease durations and…
April 21, 2021 News by Forest Ray PhD #AANAM – Kesimpta, Added to NHS in UK, Prevents Worsening in New Patients Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Note: This story was updated April 21, 2021, to clarify that Kesimpta will be available in the next three months…
April 20, 2021 News by Marta Figueiredo, PhD #AANAM – Blacks, Whites Respond Differently to B-cell Targeting Therapies Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Common B-cell depleting therapies, such as rituximab and Ocrevus (ocrelizumab), may result in shorter duration B-cell depleting effects in…
April 20, 2021 News by Marisa Wexler, MS #AANAM – Measuring Blood Proteins Could Predict Disability in SPMS Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Among people with secondary progressive multiple sclerosis (SPMS) without active disease, high blood levels of the…
